December 27, 2014 2:27 PM ET

Pharmaceuticals

Company Overview of Akrimax Pharmaceuticals, LLC

Company Overview

Akrimax Pharmaceuticals, LLC, a pharmaceutical company, develops, produces, and distributes pharmaceutical products. It offers InnoPran XL, extended release capsules that controls blood pressure and heart rate; Suprenza, an orally disintegrating tablet; Primlev, an oxycodone HCI/acetaminophen for the treatment of liver failure; Tirosint, levothyroxine sodium capsules for the treatment of hypothyroidism and Pituitary thyrotropin-stimulating hormone suppression; NitroMist, a nitroglycerin lingual spray for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease; and Inderal LA, a long-acting form of propranolol used for that treatment of angina pectoris...

11 Commerce Drive

1st Floor

Suite 100

Cranford, NJ 07016

United States

Founded in 2007

Phone:

908-372-0506

Fax:

908-282-7237

Key Executives for Akrimax Pharmaceuticals, LLC

Co-Founder and Chairman
Age: 62
Co-Founder and Vice Chairman
Age: 69
Vice President of Operations
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Akrimax Pharmaceuticals, LLC Key Developments

Akrimax Pharmaceuticals, LLC Announces New Data Highlight Use of Tirosint(R)

Akrimax Pharmaceuticals, LLC announced data that show a lower dose of Tirosint(R) (levothyroxine sodium) capsules is required as compared with standard T4 tablets for hypothyroidism patients with impaired gastric acid secretion to reach their target thyroid-stimulating hormone (TSH) levels. The American Association of Clinical Endocrinologist (AACE) Guidelines for Clinical Practice for Evaluation and Treatment of Hypothyroidism call for physicians to treat hypothyroidism with oral levothyroxine replacement therapy. Careful dose titration and monitoring is necessary in order to maintain a euthyroid state, while avoiding adverse events due to overtreatment.(1) TSH levels in patients receiving levothyroxine should be no more than 4.0 mU/L.(2). The pilot study examined patients who had T4 malabsorption and were in T4 treatment for more than 5 years with the same brand of tablets. A total of 36 patients met the study criteria, and 30 (28 females /2 males; median age=51 years; median T4 dose=2.05 mg/kg/day) completed the study. T4 treatment was switched from the usual tablets to a lower dose of the softgel T4 capsules (median T4 dose=1.77 mg/kg/day; p=0.0082). Thyroid function and TSH were measured before and after 3, 6, 12 and 18 months from the treatment switch. A slight serum TSH increase was observed in some patients after 3 months of treatment, with no change in Free T4 (FT4) levels. After 6 months, however, despite the reduced dose of T4, mean TSH values were similar (1.82 vs. 1.86 mU/l) in about two out of three patients (responders n=21) and so remained until the end of the study. In all of the remaining patients (non-responders n=9), TSH levels were significantly higher than baseline values throughout the study. In 4 of them, additional intestinal disorders were detected. Mean levels of FT4 and FT3 were in the normal range and not significantly modified throughout the study.

Similar Private Companies By Industry

Company Name Region
Wiley Organics, Inc. United States
Vidara Therapeutics Inc. United States
Agensys, Inc. United States
Inologic Inc. United States
Coldstream Laboratories Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Akrimax Pharmaceuticals, LLC, please visit www.akrimax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.